Novartis
NVS
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
4
In their latest 13F (Q3 2026)
See who
Value held
$134m
Combined value at quarter end
Last quarter
0 bought
4 sold or trimmed
Fund portfolios
3
Funds holding it
See which
Price at Q2 ’26 end
$156.72
+2.6% in the quarter
Share price change by quarter
+8.0%Q3 ’24
-15.4%Q4 ’24
+14.6%Q1 ’25
+8.5%Q2 ’25
+6.0%Q3 ’25
+7.5%Q4 ’25
+10.8%Q1 ’26
+2.6%Q2 ’26
Managers holding it, by quarter
5Q4 ’23
4Q1 ’24
4Q2 ’24
4Q3 ’24
4Q4 ’24
4Q1 ’25
5Q2 ’25
4Q3 ’25
5Q4 ’25
4Q1 ’26
4Q2 ’26
0Q3 ’26
Who holds it
| Tweedy, Browne | 0.8%$11.1m | Trimmed -0.3% |
| Kahn Brothers | 0.3%$2.1m | Trimmed -1.5% |
| Dodge & Cox | 0.1%$119m | Trimmed -89% |
| Horizon Kinetics | 0.0%$1.7m | Trimmed -3.7% |
About the company
- Sector
- Health care · Pharmaceutical Preparations
- Financial year ends
- 31 December
- Shares outstanding
- 1.91bn at 31 Dec 2025
- SEC filings
- Annual reports and other filings on EDGAR
In fund portfolios
| Tweedy, Browne International Value FundTweedy, Browne | 3.2% |
| Dodge & Cox International Stock FundDodge & Cox | 2.1% |
| Tweedy, Browne International Value Fund IITweedy, Browne | 1.8% |